Skip to content

Study · Observational study · n = 50 · 2025

2 results

Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.

Dăniluc L, Braha A, Sandu OE, Bogdan C, Suhov L, Haj Ali L, Lazăr-Höcher AI, Sima A, Apostol A, Ivan MV

Medicina (Kaunas, Lithuania)22 Mar 2025Cited by 1 (Europe PMC)

PMID40282858 (opens in a new tab)PMCIDPMC12028782 (opens in a new tab)DOI10.3390/medicina61040567 (opens in a new tab)PepBankPUB-40282858
Download PDFPubMedAsk about this study
Jump to 2 results

Summary

Background and Objectives: Heart failure (HF) among patients with type 2 diabetes (T2DM) is linked to significant morbidity and mortality, despite the increased availability of new drug therapy. This study aims to investigate subclinical changes in patients with HF stage A (at risk for HF) and B (Pre-HF) and T2DM treated with oral semaglutide. Materials and Methods: In a prospective, observational, single-center study, 50 T2DM patients were assessed at baseline and one-year follow-up for changes in spectral Doppler, tissue Doppler, and speckle-tracking (2DST) and metabolic parameters. Results: Correlation and regression analyses identified predictors of Δ GLS. In correlation analysis, Δ GLS showed a negative correlation with Δ VAI (rho = -0.3, p = 0.02), Δ LAP (rho = -0.3, p = 0.04), Δ FPG (rho = -0.3, p = 0.009), Δ TG (rho = -0.4, p = 0.004), and Δ TyG (rho = -0.3, p = 0.02). In linear stepwise regression analysis, the most accurate model, with a p-value 3, explaining 70% of the variance in Δ GLS (adjusted R2 = 0.7); this model included Δ FPG (beta -0.4, p = 0.001), Δ CRR (beta -1.3, p p = 0.01). Conclusions: These findings show that improved subclinical left ventricular systolic dysfunction is associated with improved glycemic control, visceral adiposity, and reduced insulin resistance, respectively, with improved lipid profiling.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyOther

    In 50 patients with type 2 diabetes and HF stage A or B on oral semaglutide, one-year change in GLS correlated negatively with changes in VAI, LAP, fasting plasma glucose, triglycerides and TyG.

    In plain wordsIn 50 people with type 2 diabetes on oral semaglutide, changes in a heart function measure (GLS) tracked changes in fat, glucose and lipids.

    Peptide
    Semaglutide
    Outcome
    Not applicableCorrelation of change in GLS with changes in metabolic indices
    Study

    n = 50

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · oral · one yearAs given in this study (human).

    Source sentences

    Summary
    In correlation analysis, Δ GLS showed a negative correlation with Δ VAI (rho = -0.3, p = 0.02), Δ LAP (rho = -0.3, p = 0.04), Δ FPG (rho = -0.3, p = 0.009), Δ TG (rho = -0.4, p = 0.004), and Δ TyG (rho = -0.3, p = 0.02).
    1 context sentence
    Summary · context
    In a prospective, observational, single-center study, 50 T2DM patients were assessed at baseline and one-year follow-up for changes in spectral Doppler, tissue Doppler, and speckle-tracking (2DST) and metabolic parameters.
  2. 02HumanObservational studyOther

    In 50 patients with type 2 diabetes and HF stage A or B on oral semaglutide, changes in fasting plasma glucose, CRR and LDL cholesterol explained 70% of the variance in change in GLS.

    In plain wordsIn 50 people on oral semaglutide, changes in glucose, CRR and LDL cholesterol were linked to changes in a heart function measure (GLS).

    Peptide
    Semaglutide
    Outcome
    Not applicablePredictors of change in GLS (regression model)
    Study

    n = 50

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · oral · one yearAs given in this study (human).

    Source sentences

    Summary
    In linear stepwise regression analysis, the most accurate model, with a p-value 3, explaining 70% of the variance in Δ GLS (adjusted R2 = 0.7); this model included Δ FPG (beta -0.4, p = 0.001), Δ CRR (beta -1.3, p p = 0.01).
    1 context sentence
    Summary · context
    In a prospective, observational, single-center study, 50 T2DM patients were assessed at baseline and one-year follow-up for changes in spectral Doppler, tissue Doppler, and speckle-tracking (2DST) and metabolic parameters.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.